Effects of Methylprednisolone combined with Cefoperazone and Sulbactam in treatment of patients with severe pneumonia
Objective:To observe effects of Methylprednisolone combined with Cefoperazone and Sulbactam in treatment of patients with severe pneumonia.Methods:The clinical data of 68 patients with severe pneumonia admitted to this hospital from August 2021 to August 2023 were retrospectively analyzed.According to different treatment methods,they were divided into control group and study group,34 cases in each group.The control group was treated with Cefoperazone and Sulbactam,while the study group was treated with Methylprednisolone sodium succinate for injection on the basis of that of the control group.The clinical efficacy,the disappearance time of clinical symptoms,the clinical pulmonary infection score(CPIS),the lung function indexes[forced expiratory volume in one second(FEV1)/forced vital capacity(FVC),peak expiratory flow(PEF),FEV1]before and after the treatment,the serum inflammatory indexes[interleukin-1β(IL-1β),tumor necrosis factor-α(TNF-α),high mobility group protein B1(HMGB1),irregular chemokine(FKN)]levels,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the study group was 88.24%,which was higher than 67.65%of the control group,and the difference was statistically significant(P<0.05).The antipyretic time,the lung rale disappearance time and the lung shadow disappearance time in the study group were shorter than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the CPIS scores of the two groups were lower than those before the treatment,that in the study group was lower than that in the control group,and the differences were statistically significant(P<0.05).The levels of FEV1/FVC,PEF and FEV1 in the two groups were higher than those before the treatment,those in the study group were higher than those in the control group,and the differences were statistically significant(P<0.05).The levels of IL-1β,FKN,TNF-α and HMGB1 in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Methylprednisolone combined with Cefoperazone and Sulbactam in the treatment of the patients with severe pneumonia can improve the total effective rate and the lung function index levels,shorten the disappearance time of clinical symptoms,and reduce the CPIS scores and the serum inflammatory index levels.Moreover,it is superior to single Cefoperazone and Sulbactam treatment.
Severe pneumoniaMethylprednisoloneCefoperazone and SulbactamLung functionInflammatory indexClinical pulmonary infection scoreAdverse reaction
万方数据
维普
